Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2023 16:15 ET | Source: iBio, Inc.

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
June 27, 2023 08:00 ET | Source: iBio, Inc.

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth

– Board appointments solidify management team to lead iBio’s AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the...
June 12, 2023 16:15 ET | Source: iBio, Inc.

iBio Forges Research Collaboration with the National Institutes of Health

– NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development – BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
June 06, 2023 08:00 ET | Source: iBio, Inc.

iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline

BRYAN, Texas and SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of...
May 09, 2023 16:30 ET | Source: iBio, Inc.

iBio to Participate in the JMP Securities Life Sciences Conference

BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its...
April 04, 2023 16:05 ET | Source: iBio, Inc.

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given...
March 31, 2023 08:10 ET | Source: iBio, Inc.

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc....
February 16, 2023 16:48 ET | Source: iBio, Inc.

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE...
January 05, 2023 08:00 ET | Source: iBio, Inc.

iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine

BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United...
December 09, 2022 16:05 ET | Source: iBio, Inc.

iBio Announces Closing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right